The Combination of Lamivudine and Hepatitis B Immune Globulin in the Prophylatic Treatment of HBsAg Positive Renal Transplant Receipts

陈劲松,陈惠萍,孙启全,季曙明,文吉秋,程东瑞,沙国柱,刘志红

DOI: https://doi.org/10.3969/j.issn.1006-298x.2010.02.005

2010-01-01

Abstract:Objective:To observe the effect of preventing the recurrence of hepatitis B with the combination of lamifudine and hepatitis B immune globulin in the HBsAg positive renal transplant receipts. Methodology:Twenty-four HBsAg positive renal transplant receipts with normal liver function,HBeAg negative and normal HBV-DNA were selected in this study.They were 20 male and 4 female with average age of(39.6±9.86) years old,and divided into two groups:received lamivudine(LAM group,n=11),and received combination of lamivudine and hepatitis B immune globulin(LAM+HBIG group n=13).All of them were received the triple immunosuppressive drugs of tacrolimus,mycophenlate mofetil and prednisone,and followed up at least for over two years.The tests of HBsAg,HBV-DNA copies,the live function were performed during the follow-up time.The recurrence rate of hepatitis B,the rate of acute rejection,and the receipts and allograft survival were compared between two groups. Results:In LAM group,the mean of follow up time was(54.4±24.0) months.Two cases died of acute liver failure and two lost their renal allograft function.The recurrence rate was 18.2%.The receipts survival were 81.8%(9/11),and the allograft survival was 63.6%(7/11).In the LAM+HBIG group,the mean of follow up time was(37.2±8.76) months.None had acute liver failure and died,and also none lost their renal allograft function.The receipt and allograft survival were both 100%. Conclusion:The combination of lamivudine and hepatitis B immune globulin in the HBsAg positive renal transplant receipt can decreased the recurrence of hepatitis B and improve the renal allograft and receipt survival.The conclusion should be made by large scale clinical trials in the future.